Chicago Partners Investment Group’s Iovance Biotherapeutics IOVA Stock Holding History

Chicago Partners Investment Group’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$301K	Buy	58,590 +5,937	+11%	+$22.6K	0.01%	1247
2026 Q1	$186K	Buy	52,653 +12,064	+30%	+$38.6K	﹤0.01%	1352
2025 Q4	$107K	Buy	40,589 +9	+0%	+$21	﹤0.01%	1263
2025 Q3	$88.9K	Sell	40,580 -409	-1%	-$966	﹤0.01%	1190
2025 Q2	$163K	Buy	40,989 +363	+0.9%	+$903	﹤0.01%	1052
2025 Q1	$127K	Buy	40,626 +20,067	+98%	+$103K	﹤0.01%	892
2024 Q4	$147K	Hold	20,559	–	–	﹤0.01%	825
2024 Q3	$202K	Hold	20,559	–	–	0.01%	763
2024 Q2	$184K	Hold	20,559	–	–	0.01%	719
2024 Q1	$244K	Hold	20,559	–	–	0.01%	630
2023 Q4	$157K	Buy	20,559 +2,688	+15%	+$14.1K	0.01%	672
2023 Q3	$61.7K	Buy	17,871 +5,000	+39%	+$32.6K	﹤0.01%	637
2023 Q2	$92.4K	Hold	12,871	–	–	﹤0.01%	660
2023 Q1	$73.4K	Hold	12,871	–	–	﹤0.01%	646
2022 Q4	$106K	Hold	12,871	–	–	0.01%	618
2022 Q3	$106K	Buy	12,871 +2,000	+18%	+$23.1K	0.01%	561
2022 Q2	$127K	Buy	+10,871	New	+$142K	0.01%	563

Other funds holding IOVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MFM

MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Chicago Partners Investment Group's IOVA Position: Q2 2026 in Review

Chicago Partners Investment Group increased its Iovance Biotherapeutics (IOVA) stake by 11% in Q2 2026, buying an estimated $22.6K and bringing the position to 58,590 shares worth $301K. The position accounts for 0.01% of the portfolio, ranked #1247.

Chicago Partners Investment Group first reported a position in IOVA in Q2 2022 and has held it in 17 quarters since. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

Chicago Partners Investment Group held 58,590 shares of Iovance Biotherapeutics worth $301K as of Q2 2026.
Chicago Partners Investment Group bought 5,937 Iovance Biotherapeutics shares in Q2 2026, an estimated $22.6K.
Iovance Biotherapeutics made up 0.01% of Chicago Partners Investment Group's portfolio in Q2 2026, its #1247 holding.
Chicago Partners Investment Group first reported a position in Iovance Biotherapeutics in Q2 2022 and has held it in 17 quarters since.
292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Chicago Partners Investment Group's 13F filing for Q2 2026, filed 30 Jul 2026.